Madrigal (MDGL) | Financial Analysis & Statements
Madrigal Pharmaceuticals Inc. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
321.1M
Gross Profit
296.6M
92.39%
Operating Income
-59.6M
-18.56%
Net Income
-58.6M
-18.24%
EPS (Diluted)
$-2.57
Balance Sheet Metrics
Total Assets
1.3B
Total Liabilities
656.9M
Shareholders Equity
602.7M
Debt to Equity
1.09
Cash Flow Metrics
Operating Cash Flow
-49.0M
Free Cash Flow
-133.1M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Madrigal Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 958.4M | 180.1M | 0 | 0 | 0 |
| Cost of Goods Sold | 56.1M | 6.2M | - | - | - |
| Gross Profit | 902.3M | 173.9M | - | - | - |
| Gross Margin % | 94.1% | 96.5% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 388.5M | 236.7M | 272.4M | 245.4M | 205.2M |
| Selling, General & Administrative | 813.8M | 435.1M | 108.1M | 48.1M | 37.3M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 1.2B | 671.8M | 380.5M | 293.6M | 242.5M |
| Operating Income | -300.1M | -497.9M | -380.5M | -293.6M | -242.5M |
| Operating Margin % | -31.3% | -276.4% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 37.4M | 46.7M | 19.6M | 2.2M | 363.0K |
| Interest Expense | 22.3M | 14.7M | 12.7M | 4.0M | 0 |
| Other Non-Operating Income | -3.2M | - | - | - | 273.0K |
| Pre-tax Income | -288.3M | -465.9M | -373.6M | -295.4M | -241.8M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -288.3M | -465.9M | -373.6M | -295.4M | -241.8M |
| Net Margin % | -30.1% | -258.6% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -261.7M | -450.1M | -360.4M | -290.9M | -241.4M |
| EPS (Basic) | $-12.85 | $-21.90 | $-19.99 | $-17.23 | $-14.63 |
| EPS (Diluted) | $-12.85 | $-21.90 | $-19.99 | $-17.23 | $-14.63 |
| Basic Shares Outstanding | 22434310 | 21272962 | 18687774 | 17137201 | 16535188 |
| Diluted Shares Outstanding | 22434310 | 21272962 | 18687774 | 17137201 | 16535188 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Madrigal Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 198.7M | 100.0M | 99.9M | 331.5M | 36.3M |
| Short-term Investments | 784.9M | 826.2M | 534.2M | 27.2M | 234.1M |
| Accounts Receivable | 134.5M | 53.8M | - | - | - |
| Inventory | 74.8M | 34.1M | - | - | - |
| Other Current Assets | 47.8M | 13.8M | 3.2M | 2.6M | 1.3M |
| Total Current Assets | 1.2B | 1.0B | 637.3M | 361.4M | 271.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 6.4M | 4.6M | 3.3M | 1.2M | 1.6M |
| Goodwill | 7.4M | 4.7M | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | - | - | - | - |
| Total Non-Current Assets | 13.8M | 9.3M | 3.3M | 1.2M | 1.6M |
| Total Assets | 1.3B | 1.0B | 640.5M | 362.6M | 273.3M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 48.9M | 43.6M | 28.0M | 23.8M | 21.4M |
| Short-term Debt | 1.0M | 983.0K | 527.0K | 602.0K | 410.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 310.3M | 169.3M | 118.5M | 115.9M | 76.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 346.6M | 118.6M | 116.7M | 49.3M | 387.0K |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 346.6M | 118.6M | 116.7M | 49.3M | 387.0K |
| Total Liabilities | 656.9M | 287.9M | 235.2M | 165.2M | 77.2M |
| Equity | |||||
| Common Stock | 2.0K | 2.0K | 2.0K | 2.0K | 2.0K |
| Retained Earnings | -2.1B | -1.8B | -1.3B | -962.7M | -667.3M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 602.7M | 754.4M | 405.3M | 197.4M | 196.1M |
| Key Metrics | |||||
| Total Debt | 347.6M | 119.6M | 117.2M | 49.9M | 797.0K |
| Working Capital | 935.5M | 863.6M | 518.7M | 245.5M | 194.8M |
Balance Sheet Composition
Madrigal Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -288.3M | -465.9M | -373.6M | -295.4M | -241.8M |
| Depreciation & Amortization | 1.5M | 1.1M | 527.0K | 467.0K | 405.0K |
| Stock-Based Compensation | 98.1M | 79.9M | 49.7M | 31.6M | 26.9M |
| Working Capital Changes | -112.4M | -72.3M | 4.2M | 2.5M | 20.4M |
| Operating Cash Flow | -296.2M | -455.6M | -316.7M | -260.0M | -194.2M |
| Investing Activities | |||||
| Capital Expenditures | -467.0K | -1.5M | -1.5M | -217.0K | -209.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -1.0B | -1.1B | -834.4M | -143.5M | -394.1M |
| Investment Sales | 1.1B | 863.3M | 333.4M | 350.4M | 389.3M |
| Investing Cash Flow | 35.3M | -269.4M | -502.5M | 206.7M | -5.1M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 350.0M | 0 | 65.0M | 50.0M | 0 |
| Debt Repayment | -121.7M | - | - | - | - |
| Financing Cash Flow | 217.9M | 397.5M | 324.8M | 304.5M | 170.2M |
| Free Cash Flow | -193.0M | -462.0M | -325.7M | -225.1M | -184.1M |
| Net Change in Cash | -42.9M | -327.5M | -494.4M | 251.2M | -29.1M |
Cash Flow Trend
Madrigal Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-40.40
Forward P/E
41.25
Price to Book
20.00
Price to Sales
12.63
PEG Ratio
7.82
Profitability Ratios
Profit Margin
-30.08%
Operating Margin
-18.57%
Return on Equity
-42.49%
Return on Assets
-16.30%
Financial Health
Current Ratio
4.02
Debt to Equity
57.68
Beta
-1.01
Per Share Data
EPS (TTM)
$-12.88
Book Value per Share
$26.39
Revenue per Share
$42.72
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| MDGL | 11.9B | -40.40 | 20.00 | -42.49% | -30.08% | 57.68 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Alnylam | 41.9B | 132.73 | 52.09 | 73.28% | 8.45% | 376.19 |
| Insmed | 31.0B | -22.40 | 40.88 | -249.28% | -210.54% | 101.43 |
| Revolution Medicines | 28.6B | -22.73 | 16.24 | -58.07% | 0.00% | 26.19 |
Financial data is updated regularly. All figures are in the company's reporting currency.






